MHRA issue safety alert highlighting the risks of hyperkalaemia

Back MHRA issue safety alert highlighting the risks of hyperkalaemia

Concomitant use of spironolactone for congestive heart failure with an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker (ARB) is not routinely recommended because of the risks of severe hyperkalaemia, particularly in patients with marked renal impairment. Use the lowest effective doses if coadministration of these medicines is considered essential and monitor blood electrolytes.

Click here to see the recent publication